Literature DB >> 17540313

[Alport syndrome or progressive hereditary nephritis with hearing loss].

Marie-Claire Gubler1, Laurence Heidet, Corinne Antignac.   

Abstract

Alport syndrome is an inherited disorder characterized by progressive hematuric nephritis with structural defects of the glomerular basement membrane, and sensorineural deafness. Ocular abnormalities are frequently associated. The incidence is approximatively 1/5000. The renal disease is severe in male patients and should be responsible for 2% of end-stage renal failure. Alport syndrome is heterogeneous at the clinical and genetic levels. It occurs as a consequence of structural abnormalities in type IV collagen, the major constituent of basement membranes. Six genetically distinct chains of type IV collagen have been identified. Mutations in the COL4A5 gene located at Xq22, and encoding the alpha 5(IV) chain are responsible for X-linked Alport syndrome whereas COL4A3 or COL4A4 located "head to head" on chromosome 2 are involved in the rarer autosomal forms of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 17540313     DOI: 10.1016/j.nephro.2007.03.005

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  3 in total

1.  Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples.

Authors:  Wen-biao Chen; Jian-rong Huang; Xiang-qi Yu; Xiao-cong Lin; Yong Dai
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

2.  Alport syndrome: significance of gingival biopsy in the initial diagnosis and periodontal evaluation after renal transplantation.

Authors:  Hilal Uslu Toygar; Okan Toygar; Esra Guzeldemir; Ulkem Cilasun; Ahmet Nacar; Nebil Bal
Journal:  J Appl Oral Sci       Date:  2009 Nov-Dec       Impact factor: 2.698

Review 3.  [Management of alport syndrome during pregnancy: a case study and literature review].

Authors:  Taher Berrada; Oumaima M'hamdi; Intissar Benzina; Fatema Zahra Lamine; Najia Zraidi; Abdelaziz Baidada
Journal:  Pan Afr Med J       Date:  2018-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.